BACKGROUND: During the treatment of diffuse large B-cell lymphoma (DLBCL) patients, treatment-related toxicities are higher in the initial phase of treatment (First cycle effect). Toxicities can be tumor lysis syndrome, deterioration in performance status, febrile neutropenia, and rarely mortality. Prephase treatment before definitive chemotherapy is used in European countries to alleviate these toxicities. METHODS: This was a non-randomized study carried out with the aim to evaluate the role of prephase treatment given prior to definitive chemotherapy in newly diagnosed DLBCL patients. Patients were divided into 2 cohorts "prephase cohort" and "non-prephase cohort." Prephase cohort received prephase treatment consisting of vincristine (1 mg) on -6th day and prednisolone 100 mg daily for 7 days (-6th day to day 0). Prephase treatment was followed by CHOP/R-CHOP chemotherapy on day 1. Non-prephase cohort received chemotherapy without prephase. Both groups were followed up for 30 days post-first cycle chemotherapy. RESULTS: A total of 100 patients with DLBCL (50 in each cohort) were enrolled. There was a significant improvement in performance status of the patients who received prephase. A majority of 92% patients attained ECOG performance status of either 0 or 1 before starting chemotherapy in the prephase cohort. Febrile neutropenia was lower (16%) in the prephase cohort as compared with the non-prephase cohort (34%; P = .037). CONCLUSION: Prephase treatment prior to definitive chemotherapy (CHOP ± Rituximab) improves the performance status and decreases first cycle effect in DLBCL patients.
BACKGROUND: During the treatment of diffuse large B-cell lymphoma (DLBCL) patients, treatment-related toxicities are higher in the initial phase of treatment (First cycle effect). Toxicities can be tumor lysis syndrome, deterioration in performance status, febrile neutropenia, and rarely mortality. Prephase treatment before definitive chemotherapy is used in European countries to alleviate these toxicities. METHODS: This was a non-randomized study carried out with the aim to evaluate the role of prephase treatment given prior to definitive chemotherapy in newly diagnosed DLBCL patients. Patients were divided into 2 cohorts "prephase cohort" and "non-prephase cohort." Prephase cohort received prephase treatment consisting of vincristine (1 mg) on -6th day and prednisolone 100 mg daily for 7 days (-6th day to day 0). Prephase treatment was followed by CHOP/R-CHOP chemotherapy on day 1. Non-prephase cohort received chemotherapy without prephase. Both groups were followed up for 30 days post-first cycle chemotherapy. RESULTS: A total of 100 patients with DLBCL (50 in each cohort) were enrolled. There was a significant improvement in performance status of the patients who received prephase. A majority of 92% patients attained ECOG performance status of either 0 or 1 before starting chemotherapy in the prephase cohort. Febrile neutropenia was lower (16%) in the prephase cohort as compared with the non-prephase cohort (34%; P = .037). CONCLUSION: Prephase treatment prior to definitive chemotherapy (CHOP ± Rituximab) improves the performance status and decreases first cycle effect in DLBCL patients.
Authors: Luis Malpica; Bolanle Mufuka; Jonathan Galeotti; Xianming Tan; Natalie Grover; Stephen M Clark; Anne Beaven; Hyman Muss; Christopher Dittus Journal: Leuk Lymphoma Date: 2020-02-09
Authors: Babu Suresh; Vikas Asati; K C Lakshmaiah; Govind Babu; D Lokanatha; Linu Abraham Jacob; K N Lokesh; A H Rudresh; L K Rajeev; Saldanha Smitha; Abhishek Anand; Rajesh Patidar; C S Premalata Journal: South Asian J Cancer Date: 2019 Jan-Mar
Authors: Sara Harrysson; Sandra Eloranta; Sara Ekberg; Gunilla Enblad; Mats Jerkeman; Bjorn E Wahlin; Per-Ola Andersson; Karin E Smedby Journal: Blood Cancer J Date: 2021-01-07 Impact factor: 11.037
Authors: Richard J Lin; Colette N Owens; Esther Drill; Augustine Iannotta; Mayan Oliveros; Dylan L Schick; Ariela Noy; John F Gerecitano; Pamela R Drullinsky; Philip C Caron; Anita Kumar; Matthew J Matasar; Craig Moskowitz; Beatriz Korc-Grodzicki; Andrew D Zelenetz; Gilles A Salles; Paul A Hamlin Journal: Haematologica Date: 2022-05-01 Impact factor: 11.047